J&J Financial News

13.01 / 20:19

markets UPS Target Food J&J testing Courts J&J buys Intra-Cellular in $14.6B deal, delving into central nervous system disorders

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by purchasing Intra-Cellular Therapies

21.01 / 13:29

WhatsApp J&J Bill Trade patient J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression

nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday.

13.01 / 18:25

markets Digital Strategy J&J Experts PAM J&J to acquire psychiatric drugs maker Intra-Cellular for $14.6 billion

Intra-Cellular Therapies Inc, a company focused on treatments for central nervous system disorders, for about $14.6 billion.

27.12 / 00:55

Analysis Food J&J Research testing Department Courts FDA proposes new testing rules to ensure cosmetics are asbestos-free

The Food and Drug Administration is proposing a rule that cosmetic companies would have to take extra steps to ensure that any products containing talc are free of asbestos

21.09 / 13:57

Strategy J&J Justice country cover testing Courts Johnson & Johnson files third bankruptcy case seeking to end talc lawsuits

Subscribe to enjoy similar stories. Johnson & Johnson filed an unprecedented third chapter 11 case seeking to end the mass lawsuits linking its cosmetic talc products to cancer, this time with the backing of tens of thousands of personal-injury plaintiffs for a roughly $8 billion compensation plan.

09.09 / 22:38

Apple J&J patient Courts Updates Pharmaceuticals Johnson & Johnson told to pay ₹35 lakh each as compensation to hip implant victims

National Consumer Disputes Redressal Commission (NCDRC) has directed Johnson & Johnson to pay ₹35 lakh in compensation to each of the patients who had approached it claiming to have adversely affected after receiving a faulty hip implant of the multinational pharmaceutical company.

17.07 / 22:32

UPS FIVE CEO Airlines J&J Trade reports ASML, Five Below fall; J&J, V.F. Corp. rise; Wednesday, 7/17/2024

Stocks that traded heavily or had substantial price changes on Wednesday: ASML, Five Below fall; J&J, V

12.07 / 16:22

UPS Provident Reuters Fighting Strategy J&J Courts The Talc tragedy: Inside the Johnson & Johnson lawsuit saga

ovarian cancer, leaving behind two daughters. Her grieving mother, Darlene, blames Johnson & Johnson's Baby Powder — and she's pursuing a lawsuit her daughter started a decade ago, alleging the company's talc caused the deadly illness. The 71-year-old Houston-area grandmother has drained her savings caring for the girls, she said. Now she and tens of thousands of other claimants face a July 26 deadline to vote on J&J's third attempt at a controversial bankruptcy maneuver that would cap its liability and set up a fund to pay victims. «I don't know how much longer I can carry on,» Evans told Reuters. «I feel pressure that I should probably vote 'yes.'»

17.06 / 16:25

markets UPS Provident Target JPMorgan J&J Relationships Midsize companies are big business for Wall Street’s megabanks

America’s biggest bank has a thing for midsize companies. Known for financing and advising megamergers, JPMorgan Chase is spending more of its resources on doing deals for companies valued at $2 billion or less. The goal is to leverage the relationships it has with the roughly 30,000 U.S.

12.06 / 18:03

Assurant Strategy Remark Moodys J&J cover 2020 Johnson & Johnson agrees to $700 million settlement over talc products

baby powder. This agreement comes after extensive scrutiny over claims that these products caused cancer.

16.05 / 09:13

markets J&J Research reports medicines Investigations Vaccines Rare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Covid-19 vaccines: scientists report to journal

J&J and AstraZeneca shots that were later pulled from the market, contain a component that can trigger blood clots in genetically susceptible individuals, scientists reported Wednesday in a letter to the New England Journal of Medicine. Researchers are now aiming to identify the specific component and attempt to remove it through genetic engineering, the report said.

02.05 / 16:19

markets UPS Digital Food J&J reports Dabur sees early signs of rural recovery, enters talcum powder market

Dabur expects mid-single digit growth in Q4 consolidated revenues For Dabur, rural markets grew 400 basis points (bps) ahead of urban markets in the March quarter. On Thursday, the company reported a 16.2% jump in quarterly net profit to ₹350 crore, up from ₹301 crore a year earlier. Revenue in the three months through March stood at ₹2,815 crore, up 5.1% from a year earlier.

02.05 / 03:23

markets Merit security J&J cover 2020 J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits

A subsidiary of Johnson & Johnson is now proposing paying approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc caused ovarian cancer

20.04 / 14:36

Manufacturing Action Election Death J&J testing Updates WHO says wider alert on contaminated J&J cough syrup 'likely'

Lok Sabha Elections 2024 Phase 1 Polling: Live updates Nigeria's regu

19.04 / 12:03

markets Aware Manufacturing Election J&J wellness sanitizer Hygiene brand Pee Safe crosses Rs 100 crore in sales, nears profitability

revenue mark.

05.04 / 16:33

markets UPS Waves J&J Inside J&J to pump another $13B into its MedTech business with Shockwave deal

Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries

05.04 / 11:59

Enterprise WhatsApp J&J Healthcare Trade reports Johnson & Johnson to buy Shockwave Medical for $12.5 bln

Shockwave Medical for $12.5 billion, in a deal that would help broaden its portfolio of medical devices used in treating heart diseases. The transaction — which is J&J's biggest since its $16.6 billion acquisition of heart pump maker Abiomed in 2022 — would give it access to a medical device that uses shockwaves to break down calcified plaque in heart vessels, similar to how kidney stones are treated.

22.03 / 13:17

markets J&J Research show testing patient prevention New blood thinners will prevent blood clots without causing bleeding

A new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without leaving patients at risk of bleeding. At least a half-dozen experimental blood thinners are in development that inhibit a protein called factor XI, one of several blood factors that regulate how the body forms clots. The challenge is this: The body generates two types of clots—good ones that plug holes in blood vessels to stop bleeding caused by external injuries, and bad ones that grow inside arteries and veins.

05.03 / 20:51

J&J Courts Latest J&J talc trial ends with hung jury

By Brendan Pierson

27.02 / 15:02

markets Strategy Mobile J&J performer track Expecting a Market Downturn? Protect Your Portfolio With These Dividend Champions

It's still early for the dividend season to kick into high gear, but it's a good time to start considering building a portfolio focused on companies that share profits with shareholders.

23.01 / 14:47

markets Patrick J&J pandemic President reports Investigations J&J profit edges past Street view after deals delay Stelara competition

By Bhanvi Satija and Patrick Wingrove

what you should know about J&J

What is J&J and why is it relevant?

J&J is a trending topic that draws public attention. On our site, we regularly publish articles related to this subject.

Where can I find the latest updates on J&J?

All new posts about J&J can be found in the highlighted block. We publish information regularly.

How can I verify the accuracy of information on J&J?

We consult with professionals to ensure that the information about J&J is well-supported and valuable for our readers.